| A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1) (NCT01919229) | Novartis Pharmaceuticals | 2013-10-01 |
| Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis (NCT01892436) | Novartis Pharmaceuticals | 2013-09-30 |
| An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. (NCT01908816) | Novartis Pharmaceuticals | 2013-09-26 |
| Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients (NCT01925209) | Novartis Pharmaceuticals | 2013-09-26 |
| Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants (NCT01888432) | Novartis Pharmaceuticals | 2013-09-25 |
| Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (NCT01922102) | Novartis Pharmaceuticals | 2013-09-11 |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer (NCT01820325) | Novartis Pharmaceuticals | 2013-09-09 |
| Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer (NCT01857193) | Novartis Pharmaceuticals | 2013-09-06 |
| A Safety and Efficacy Study of Eltrombopag in Subjects With AML (NCT01890746) | Novartis Pharmaceuticals | 2013-09-05 |
| NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer (NCT01816594) | Novartis Pharmaceuticals | 2013-09-03 |
| Post Hematopoietic Stem Cell Transplantation (NCT01610297) | Novartis Pharmaceuticals | 2013-09-01 |
| A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors (NCT01911936) | Novartis Pharmaceuticals | 2013-09-01 |
| Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization. (NCT01840410) | Novartis Pharmaceuticals | 2013-09-01 |
| Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan (NCT01876368) | Novartis Pharmaceuticals | 2013-09-01 |
| Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) (NCT01742286) | Novartis Pharmaceuticals | 2013-08-28 |
| Safety and Efficacy of BAF312 in Dermatomyositis (NCT02029274) | Novartis Pharmaceuticals | 2013-08-25 |
| Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP) (NCT01952015) | Novartis Pharmaceuticals | 2013-08-21 |
| Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (NCT01844765) | Novartis Pharmaceuticals | 2013-08-20 |
| 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (NCT01563354) | Novartis Pharmaceuticals | 2013-08-16 |
| Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris (NCT01920477) | Novartis Pharmaceuticals | 2013-08-13 |
| A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation (NCT01744665) | Novartis Pharmaceuticals | 2013-08-12 |
| Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) (NCT01846273) | Novartis Pharmaceuticals | 2013-08-07 |
| Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON) (NCT01757691) | Novartis Pharmaceuticals | 2013-08-01 |
| Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01922271) | Novartis Pharmaceuticals | 2013-08-01 |
| PK of Serelaxin in Severe Renal Impairment and ESRD (NCT01875523) | Novartis Pharmaceuticals | 2013-08-01 |
| A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture (NCT01845623) | Novartis Pharmaceuticals | 2013-08-01 |
| Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib (NCT01831726) | Novartis Pharmaceuticals | 2013-08-01 |
| To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension (NCT02047656) | Novartis Pharmaceuticals | 2013-08-01 |
| Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI) (NCT01844778) | Novartis Pharmaceuticals | 2013-08-01 |
| Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) (NCT01822613) | Novartis Pharmaceuticals | 2013-07-26 |
| Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis (NCT01892722) | Novartis Pharmaceuticals | 2013-07-26 |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer (NCT01828099) | Novartis Pharmaceuticals | 2013-07-09 |
| A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (NCT01904214) | Novartis Pharmaceuticals | 2013-07-01 |
| Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus (NCT01915849) | Novartis Pharmaceuticals | 2013-07-01 |
| A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection (NCT01860989) | Novartis Pharmaceuticals | 2013-07-01 |
| Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS (NCT01709812) | Novartis Pharmaceuticals | 2013-07-01 |
| Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients (NCT01910441) | Novartis Pharmaceuticals | 2013-07-01 |
| QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations) (NCT01782326) | Novartis Pharmaceuticals | 2013-07-01 |
| A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies (NCT01830010) | Novartis Pharmaceuticals | 2013-06-28 |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib (NCT01828112) | Novartis Pharmaceuticals | 2013-06-28 |
| Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment (NCT01863745) | Novartis Pharmaceuticals | 2013-06-25 |
| Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Continue to Benefit From the Treatment as Judged by the Investigator (NCT01802879) | Novartis Pharmaceuticals | 2013-06-24 |
| Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (NCT01807520) | Novartis Pharmaceuticals | 2013-06-20 |
| Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (NCT01806597) | Novartis Pharmaceuticals | 2013-06-19 |
| A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP) (NCT02201290) | Novartis Pharmaceuticals | 2013-06-18 |
| Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration (NCT01780935) | Novartis Pharmaceuticals | 2013-06-03 |
| Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients (NCT01811472) | Novartis Pharmaceuticals | 2013-06-01 |
| Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer (NCT01772797) | Novartis Pharmaceuticals | 2013-06-01 |
| Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis (NCT01828086) | Novartis Pharmaceuticals | 2013-06-01 |
| Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin (NCT01871558) | Novartis Pharmaceuticals | 2013-06-01 |
| Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis (NCT01874340) | Novartis Pharmaceuticals | 2013-06-01 |
| ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon (NCT01621269) | Novartis Pharmaceuticals | 2013-06-01 |
| An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old (NCT01724138) | Novartis Pharmaceuticals | 2013-06-01 |
| Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis. (NCT01785602) | Novartis Pharmaceuticals | 2013-06-01 |
| Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma (NCT01747876) | Novartis Pharmaceuticals | 2013-05-28 |
| A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects (NCT01677741) | Novartis Pharmaceuticals | 2013-05-23 |
| Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. (NCT01789281) | Novartis Pharmaceuticals | 2013-05-14 |
| Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin (NCT01766778) | Novartis Pharmaceuticals | 2013-05-13 |
| A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF (NCT01787552) | Novartis Pharmaceuticals | 2013-05-08 |
| Canadian Treat and Extend Analysis Trial With Ranibizumab (NCT02103738) | Novartis Pharmaceuticals | 2013-05-08 |
| A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB) (NCT01708174) | Novartis Pharmaceuticals | 2013-05-06 |
| Study of Safety of Foradil in Patients With Persistent Asthma (NCT01845025) | Novartis Pharmaceuticals | 2013-05-01 |
| Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia (NCT01566630) | Novartis Pharmaceuticals | 2013-05-01 |
| A Phase I Study of LEE011 in Asian Patients (NCT01898845) | Novartis Pharmaceuticals | 2013-05-01 |
| Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors. (NCT01700270) | Novartis Pharmaceuticals | 2013-05-01 |
| A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients (NCT01836471) | Novartis Pharmaceuticals | 2013-05-01 |
| Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy (NCT01811485) | Novartis Pharmaceuticals | 2013-05-01 |
| Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia (NCT01826214) | Novartis Pharmaceuticals | 2013-05-01 |
| Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes (NCT01862263) | Novartis Pharmaceuticals | 2013-05-01 |
| A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (NCT01713946) | Novartis Pharmaceuticals | 2013-04-29 |
| Efficacy and Tolerability of BAF312 in Patients With Polymyositis (NCT01801917) | Novartis Pharmaceuticals | 2013-04-24 |
| A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (NCT01743989) | Novartis Pharmaceuticals | 2013-04-15 |
| Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis (NCT01752634) | Novartis Pharmaceuticals | 2013-04-14 |
| Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients (NCT01769768) | Novartis Pharmaceuticals | 2013-04-01 |
| Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension (NCT01785472) | Novartis Pharmaceuticals | 2013-04-01 |
| Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients (NCT01727024) | Novartis Pharmaceuticals | 2013-04-01 |
| An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (NCT01640964) | Novartis Pharmaceuticals | 2013-04-01 |
| Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS (NCT01757015) | Novartis Pharmaceuticals | 2013-04-01 |
| Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients (NCT01582243) | Novartis Pharmaceuticals | 2013-04-01 |
| Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study (NCT01735955) | Novartis Pharmaceuticals | 2013-03-29 |
| BKM120 for Patients With PI3K-activated Tumors (NCT01833169) | Novartis Pharmaceuticals | 2013-03-29 |
| Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (NCT03176238) | Novartis Pharmaceuticals | 2013-03-29 |
| Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator (NCT01742299) | Novartis Pharmaceuticals | 2013-03-26 |
| Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. (NCT01737827) | Novartis Pharmaceuticals | 2013-03-25 |
| A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients (NCT02566031) | Novartis Pharmaceuticals | 2013-03-23 |
| A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors (NCT01760525) | Novartis Pharmaceuticals | 2013-03-20 |
| Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (NCT01784068) | Novartis Pharmaceuticals | 2013-03-19 |
| Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer (NCT01646684) | Novartis Pharmaceuticals | 2013-03-08 |
| Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer (NCT01698918) | Novartis Pharmaceuticals | 2013-03-07 |
| Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection (NCT01753323) | Novartis Pharmaceuticals | 2013-03-01 |
| Effect of Hepatic Impairment on LDE225.. (NCT01764776) | Novartis Pharmaceuticals | 2013-03-01 |
| Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients (NCT01825980) | Novartis Pharmaceuticals | 2013-03-01 |
| EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes (NCT01711606) | Novartis Pharmaceuticals | 2013-03-01 |
| An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction (NCT01846468) | Novartis Pharmaceuticals | 2013-03-01 |
| Safety and Efficacy of BKM120 in Relapsed and Refractory NHL (NCT01693614) | Novartis Pharmaceuticals | 2013-02-28 |
| A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients (NCT01735968) | Novartis Pharmaceuticals | 2013-02-27 |
| A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. (NCT01783444) | Novartis Pharmaceuticals | 2013-02-26 |
| Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration) (NCT01775124) | Novartis Pharmaceuticals | 2013-02-22 |
| Eltrombopag Phase III Study In Chinese Chronic ITP Patients (NCT01762761) | Novartis Pharmaceuticals | 2013-02-18 |
| A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator (NCT01794780) | Novartis Pharmaceuticals | 2013-02-05 |